These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 11352906)

  • 1. Targeting of functional antibody-decay-accelerating factor fusion proteins to a cell surface.
    Zhang H; Lu S; Morrison SL; Tomlinson S
    J Biol Chem; 2001 Jul; 276(29):27290-5. PubMed ID: 11352906
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting of functional antibody-CD59 fusion proteins to a cell surface.
    Zhang HF; Yu J; Bajwa E; Morrison SL; Tomlinson S
    J Clin Invest; 1999 Jan; 103(1):55-61. PubMed ID: 9884334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complement receptor 2-mediated targeting of complement inhibitors to sites of complement activation.
    Song H; He C; Knaak C; Guthridge JM; Holers VM; Tomlinson S
    J Clin Invest; 2003 Jun; 111(12):1875-85. PubMed ID: 12813023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coupling complement regulators to immunoglobulin domains generates effective anti-complement reagents with extended half-life in vivo.
    Harris CL; Williams AS; Linton SM; Morgan BP
    Clin Exp Immunol; 2002 Aug; 129(2):198-207. PubMed ID: 12165074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of various forms of the C1 esterase inhibitor (C1-INH) and DAF on complement mediated xenogeneic cell lysis.
    Fukuta D; Miyagawa S; Yamada M; Matsunami K; Kurihara T; Shirasu A; Hattori H; Shirakura R
    Xenotransplantation; 2003 Mar; 10(2):132-41. PubMed ID: 12588646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human and rodent decay-accelerating factors (CD55) are not species restricted in their complement-inhibiting activities.
    Harris CL; Spiller OB; Morgan BP
    Immunology; 2000 Aug; 100(4):462-70. PubMed ID: 10929073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of a hybrid complement regulatory protein, membrane cofactor protein decay accelerating factor on Chinese hamster ovary. Comparison of its regulatory effect with those of decay accelerating factor and membrane cofactor protein.
    Iwata K; Seya T; Ariga H; Nagasawa S
    J Immunol; 1994 Apr; 152(7):3436-44. PubMed ID: 7511647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human lung cancer cell lines express cell membrane complement inhibitory proteins and are extremely resistant to complement-mediated lysis; a comparison with normal human respiratory epithelium in vitro, and an insight into mechanism(s) of resistance.
    Varsano S; Rashkovsky L; Shapiro H; Ophir D; Mark-Bentankur T
    Clin Exp Immunol; 1998 Aug; 113(2):173-82. PubMed ID: 9717965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chimeric CD46/DAF molecules reveal a cryptic functional role for SCR1 of DAF in regulating complement activation.
    Christiansen D; Loveland B; Kyriakou P; Lanteri M; Rubinstein E; Gerlier D
    Mol Immunol; 2000; 37(12-13):687-96. PubMed ID: 11275254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cooperation between human DAF and CD59 in protecting cells from human complement-mediated lysis.
    Xu L; Wu W; Zhao Z; Shao H; Liu W; Liu H; Li W
    J Biochem Mol Biol; 2006 Nov; 39(6):743-8. PubMed ID: 17129411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Test for ability of decay-accelerating factor (DAF, CD55) and CD59 to alleviate complement-mediated damage of xeno-erythrocytes.
    Miyagawa S; Shirakura R; Matsumiya G; Nakata S; Matsuda H; Hatanaka M; Matsumoto M; Kitamura H; Seya T
    Scand J Immunol; 1993 Jul; 38(1):37-44. PubMed ID: 7687071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cell-surface expression of an amino-terminal fragment of apolipoprotein B increases lipoprotein lipase binding to cells.
    Pang L; Sivaram P; Goldberg IJ
    J Biol Chem; 1996 Aug; 271(32):19518-23. PubMed ID: 8702644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protective effect of scFv-DAF fusion protein on the complement attack to acetylcholine receptor: a possible option for treatment of myasthenia gravis.
    Song C; Xu Z; Miao J; Xu J; Wu X; Zhang F; Lin H; Li Z; Kaminski HJ
    Muscle Nerve; 2012 May; 45(5):668-675. PubMed ID: 22499093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of tandem forms of DAF(CD55) on complement-mediated xenogeneic cell lysis.
    Miyagawa S; Fukuta D; Kitano E; Kobayashi C; Fumimoto Y; Shirasu A; Hattori H; Shirakura R; Fukuzawa M
    Xenotransplantation; 2006 Sep; 13(5):433-9. PubMed ID: 16925667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rat T cells express neither CD55 nor CD59 and are dependent on Crry for protection from homologous complement.
    Hanna S; Spiller O; Linton SM; Mead RJ; Morgan B
    Eur J Immunol; 2002 Feb; 32(2):502-9. PubMed ID: 11828367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Delta-short consensus repeat 4-decay accelerating factor (DAF: CD55) inhibits complement-mediated cytolysis but not NK cell-mediated cytolysis.
    Miyagawa S; Kubo T; Matsunami K; Kusama T; Beppu K; Nozaki H; Moritan T; Ahn C; Kim JY; Fukuta D; Shirakura R
    J Immunol; 2004 Sep; 173(6):3945-52. PubMed ID: 15356143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of decay-accelerating factor as a receptor for Helicobacter pylori and a mediator of gastric inflammation.
    O'Brien DP; Israel DA; Krishna U; Romero-Gallo J; Nedrud J; Medof ME; Lin F; Redline R; Lublin DM; Nowicki BJ; Franco AT; Ogden S; Williams AD; Polk DB; Peek RM
    J Biol Chem; 2006 May; 281(19):13317-13323. PubMed ID: 16543227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protection of xenogeneic cells from human complement-mediated lysis by the expression of human DAF, CD59 and MCP.
    Huang J; Gou D; Zhen C; Jiang D; Mao X; Li W; Chen S; Cai C
    FEMS Immunol Med Microbiol; 2001 Oct; 31(3):203-9. PubMed ID: 11720816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phospholipid-anchored and transmembrane versions of either decay-accelerating factor or membrane cofactor protein show equal efficiency in protection from complement-mediated cell damage.
    Lublin DM; Coyne KE
    J Exp Med; 1991 Jul; 174(1):35-44. PubMed ID: 1711565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ScFv-mediated in vivo targeting of DAF to erythrocytes inhibits lysis by complement.
    Spitzer D; Unsinger J; Bessler M; Atkinson JP
    Mol Immunol; 2004 Feb; 40(13):911-9. PubMed ID: 14725787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.